| Lutetium (177lu) Oxodotreotide studied in …STUDIED_INderived36 of 36show fewer |
|---|
| → studied in | NCT03971461Phase 2 · active not recruiting Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma · 36 trials list this drug (22 active) | — | — | Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583708Phase 2 · recruiting Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer · 36 trials list this drug (22 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05773274Phase 2 · recruiting Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Tumor G1,Digestive System Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04234568Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Neoplasm,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665739Phase 2 · recruiting Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Functioning Lung Neuroendocrine Tumor,Lung Neuroendocrine Neoplasm,Non-Functioning Lung Neuroendocrine Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05687123Phase 1 · recruiting Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Pancreatic Neoplasm,Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05247905Phase 2 · active not recruiting Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial · 36 trials list this drug (22 active) | — | — | Pancreatic Neuroendocrine Carcinoma,Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04609592Phase 1 · active not recruiting Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05724108Phase 2 · active not recruiting Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05278208Phase 1/Phase 2 · recruiting Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors · 36 trials list this drug (22 active) | — | — | Embryonal Neoplasm,Anaplastic Ependymoma,Medulloblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05691465Phase 2 · recruiting Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells · 36 trials list this drug (22 active) | — | — | Prostate Neuroendocrine Carcinoma,Malignant Prostate Neoplasm,Prostate Adenocarcinoma with Neuroendocrine Differentiation+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016855Phase 4 · recruiting Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Neoplasm,Digestive System Neuroendocrine Tumor G1,Digestive System Neuroendocrine Tumor G2+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06122610Phase 1 · completed Using Novel Imaging to More Safely Treat Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04750954Phase 1 · active not recruiting Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Neuroendocrine Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06326190Phase 2 · recruiting 177Lu-DOTATATE for Recurrent Meningioma · 36 trials list this drug (22 active) | — | — | Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04529044Phase 2 · recruiting 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer · 36 trials list this drug (22 active) | — | — | Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04954820Phase 2 · recruiting Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544098early Phase 1 · active not recruiting Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04727723completed Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04082520Phase 2 · recruiting Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy · 36 trials list this drug (22 active) | — | — | Meningioma,Grade 1 Meningioma,Grade 2 Meningioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150546Phase 1 · recruiting Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Neoplasm,Digestive System Neuroendocrine Tumor,Digestive System Neuroendocrine Tumor G1+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03972488Phase 3 · active not recruiting Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET · 36 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987176Phase 2 · terminated Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases · 36 trials list this drug (22 active) | — | — | Digestive System Neuroendocrine Neoplasm,Digestive System Neuroendocrine Tumor,Neuroendocrine Tumor+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06663072Phase 1 · recruiting Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Pancreatic Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03691064active not recruiting Post-Authorization Long-Term Safety Study of LUTATHERA · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07012330Phase 2 · terminated Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04614766Phase 1/Phase 2 · withdrawn A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04385992Phase 2 · completed Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05513469NA · unknown Biomarker Identification of Radionuclide Therapy-induced Radiation Responses · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01237457Phase 2 · completed 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03590119Phase 2/Phase 3 · completed Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04525638Phase 2 · unknown A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours · 36 trials list this drug (22 active) | — | — | Neuroendocrine Carcinoma,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03923257Phase 1/Phase 2 · withdrawn Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor,Paraganglioma,Adrenal Gland Pheochromocytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04106843Phase 2 · withdrawn Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers · 36 trials list this drug (22 active) | — | — | Paraganglioma,Parathyroid Gland Carcinoma,Thyroid Gland Medullary Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04039516Phase 2 · unknown Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01860742Phase 3 · withdrawn Randomized Phase III of PRRT Versus Interferon · 36 trials list this drug (22 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |